JPRN-jRCT2031180066进行中(未招募)1 期
Prospective study of Romiplostim for rapid platelet recovery after cord blood transplantation, phase 1 - PROMPT-1
Chiba Shigeru0 个研究点目标入组 6 人开始时间: 2018年12月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16age old 至 65age old(—)
- 性别
- All
入选标准
- •1. Preliminary inclusion criteria
- •1) Patients with AML (blast < 5%), ALL (blast < 5%), MDS (blast < 5%), or NHL (complete response or partial response)
- •2) Patients 16 to 65 years of age
- •3) Patients who do not have HLA antigen-matched (6/6) appropriate related donors
- •4) Patients who do not have HLA allele-matched (8/8) unrelated donors.
- •5) Patients with ECOG of 0, 1, or 2
- •6) Patients without severe dysfunction in the heart, the lung, the liver, and the kidney
- •(a) ejection fraction >= 40%
- •(b) SaO2 (or SpO2) >= 94%
- •(c) %VC >= 70%, and FEV1.0% >= 70%
- •(d) total bilirubin < x1.5 of the upper limit
- •(e) ALT < x3 of the upper limit
- •(f) AST < x3 of the upper limit
- •(g) creatinine < 2.0 mg/dL
- •7) Patients who gave written informed consent
- •2. Secondary inclusion criteria
- •1) SaO2 (or SpO2) >= 94%
- •2) total bilirubin < x1.5 of the upper limit
- •3) ALT < x3 of the upper limit
- •4) AST < x3 of the upper limit
- •5) creatinine < 2.0 mg/d
排除标准
- •1. Preliminary exclusion criteria
- •1) Patients with anti-HLA antibody
- •2) Patients with uncontrollable psychological complications
- •3) Patients with active double cancer
- •4) Patients with uncontrollable active infection
- •5) Patients with bone marrow fibrosis (reticulin grade >= 2)
- •6) Patients with prior history of allogeneic hematopoietic transplantation
- •7) Patients with severe cardiac complications
- •8) Patient with prior thrombotic history or with predisposing factors to thrombosis
- •9) Patients with positive for HIV antibody, HBs antigen, or HCV-RNA
- •10) Patients with uncontrollable diabetes mellitus
- •11) Patients with uncontrollable hypertension
- •12) Patients who were enrolled to other clinical trials within 3 months
- •13) Patients with prior history of TPO-R administration
- •14) Patients with hypersensitivity to recombinant protein derived from E-coli
- •15) Pregnant women, patients during lactation, or patients who deny anticonception
- •16) Patients who are judged inappropriate by investigators
- •2. Secondary exclusion criteria
- •1) Patients who are judged inappropriate by investigators
研究者
相似试验
已完成
不适用
Prospective study of ROMiplostim for rapid Platelet recovery after cord blood Transplantation, phase 1acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), non-Hodgkin lymphoma (NHL)JPRN-UMIN000033799niversity of Tsukuba Hospital6
尚未招募
4 期
se of platelet-improving medicine Romiplostim in Liver Transplant PatientCTRI/2024/04/066269Amrita School of Pharmacy
招募中
2 期
Romiplostim in treatment-naïve acquired aplastic anemiaIRCT20221129056655N2Shiraz University of Medical Sciences23
招募中
2 期
Romiplostim in treatment-refractory acquired aplastic anemiaIRCT20221129056655N1Shiraz University of Medical Sciences24
招募中
2 期
An invivo study to evaluate the effect of Platelet Rich Fibrin on dental implant stability when it is used as a filler in implant socket so as to modify the implant surface by using Radio Frequency Analysis.CTRI/2014/06/004684Dr Shashi Bhushan Gupta40
